Eyenovia stopped a Phase 3 trial following a review of the data that found its experimental myopia treatment wasn’t going to hit the study’s primary endpoint. The ophthalmic company is now considering strategic options. Its stock $EYEN was down about 73% on Friday morning following the announcement. Eyenovia had been investigating a drug-device combination that dispensed atropine as a treatment for pediatric progressive myopia, a form of nearsightedness that grows worse over time due to abnorm

ROCKVILLE, Md. & EDMONTON, Alberta--( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE), and reinforce the clinical importance of LUPKYNIS ® (

Boston Pharmaceuticals succeeded on two closely watched efficacy endpoints for its Phase 2 MASH study, putting the company in contention with other biotechs seeking to treat the liver disease. The company reported Friday that its FGF21 analog, called efimosfermin alfa, spurred a statistically significant improvement in both fibrosis without worsening of MASH, and resolution of MASH without worsening of fibrosis. The new data assessed the once-monthly shot over 24 weeks in 84 patients with advanc

Improvements Nationally in Healthcare-Associated Infections, Hand Hygiene and Medication Safety WASHINGTON, Nov. 15, 2024 /PRNewswire/ -- The Leapfrog Group, an independent nonprofit focused on patient safety, today released its fall 2024 Hospital Safety Grade, evaluating nearly 3,000 hospitals on their ability to prevent medical errors, accidents and infections. The Hospital Safety Grade uses up to 30 performance measures to assign an "A, "B," "C," "D" or "F" to individual hospitals and uses a

Plus, news about Bavarian Nordic, Nuvectis Pharma, Flashpoint Therapeutics, Sparian Biosciences and TFF Pharmaceuticals: Vitalli Bio axes Daewoong asset: Vitalli, founded by Joe Jimenez’s Aditum Bio , plans to terminate its licensing agreement for an autoimmune disease drug developed by Daewoong Pharmaceutical, according to a regulatory filing . The deal was worth up to $477 million for Daewoong. Vitalli still has the option for two additional candidates from Daewoong, the company said. Jim

LONDON, UK I November 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma. The trial met the key secondary endpoint of overall survival (OS), showing that belantamab mafodotin when combined with BorDex significantly r

Numab to receive R&D funding for the preclinical development of ND081 Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global development up to clinical POC HORGEN, Switzerland and TOKYO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a clinical stage biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, and Kaken Pharmaceutical Co., Ltd. (“Kaken”), an

The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of patient enrollment as planned. There has been no safety concern with the use of Leuprolide (FP-001) injectable Emulsion in pediatric CPP patients. TAIPEI, Nov. 15, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announces the second positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study. The DSMB recommended that Fore

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infantsClinical estimates for SP-B deficiency have an incidence of 1 in 1 million live births in the US and EuropeHighly encouraging preclinical data highlight the possibility of lifelong treatment from a single administration of AVG-002Preparations for the clinical development of AVG-002 are underway with the possibility of filing for marketing authorisation by 2028 RPDD provides eligibi

BASEL, Switzerland I November 15, 2024 I Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has granted marketing authorization for Afqlir® (aflibercept) 2 mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar to reference medicine Eylea®*[1,2]. Afqlir® is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD), aiming to prevent disease-rel